Halogenopyrazole Thrombin Inhibitors Oral Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anticoagulant therapies, such as warfarin and heparin, have limitations including long half-lives, drug interactions, and bleeding complications, necessitating the development of orally available drugs with a wide therapeutic window for safer and more effective thrombin inhibition.
Innovation Solution
Development of multisubstituted aromatic compounds, specifically represented by Formula (IIa), which act as direct thrombin inhibitors, offering a potential solution for treating thrombotic disorders by inhibiting thrombin activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If warfarin is used as an anticoagulant, then it provides therapeutic effect by inhibiting clotting factors, but it has long half-life and serious drug-drug interactions
Solution Approach 1:
The patent applies parameter changes by developing novel chemical compounds with modified molecular structures (Formula I and Formula II) that have altered pharmacokinetic properties compared to warfarin. The structural modifications include different heterocyclic rings and substituent patterns designed to achieve shorter half-life and reduced drug interactions while maintaining anticoagulant activity.
2Reliability
If heparin is used to activate AT III for inhibiting clotting factors, then it provides therapeutic effect, but it requires parenteral administration and close supervision
Solution Approach 1:
The patent uses small molecule organic compounds as intermediaries that can orally inhibit thrombin directly, eliminating the need for heparin's protein-mediated mechanism requiring injection. The small molecules serve as simplified mediators that achieve the same therapeutic goal through oral administration with better patient compliance.
3Reliability
If Vitamin K antagonism is used to inhibit multiple clotting factors, then it provides broad anticoagulant effect, but it causes significant bleeding complications
Solution Approach 1:
The patent extracts and targets only thrombin (factor IIa) specifically, rather than using Vitamin K antagonism that affects multiple factors (II, VII, IX, X). This selective inhibition of thrombin alone provides adequate anticoagulant protection while reducing bleeding risks associated with broad-factor inhibition.
4Reliability
If direct thrombin inhibitors are developed based on D-Phe-Pro-Arg motif, then they target thrombin specifically, but they lack oral availability and wide therapeutic window
Solution Approach 1:
The patent creates composite molecular structures combining the thrombin-binding peptide motif (D-Phe-Pro-Arg) with heterocyclic aromatic cores and various substituents (Formula I and Formula II). This composite design enhances oral bioavailability and therapeutic index while preserving specific thrombin inhibition, overcoming the limitations of simple peptide-based DTIs.
Data Source
AI summary
There are provided inter alia multisubstituted aromatic compounds useful for the inhibition of thrombin, which compounds include substituted pyrazolyi. There are additionally provided pharmaceutical compositions. There are additionally provided methods of treating and preventing a disease or disorder, which disease or disorder is amenable to treatment or prevention by the inhibition of thrombin.